Kush Parmar
Chairman en ENTRADA THERAPEUTICS, INC. .
Fortuna: - $ al 31/03/2024
Perfil
Kush M.
Parmar was the founder of Cruz Blanca Initiative, Inc. (founded in 2000) and held the title of President.
He is also the founder of Immuneel Therapeutics Pvt Ltd., Ensoma, Inc...
Dr. Parmar's current job positions include Chairman at Entrada Therapeutics, Inc. (since 2016), Independent Non-Executive Director at Syngene International Ltd.
(since 2021), Director at Astellas Gene Therapies, Inc. (since 2013), Director at Rallybio LLC, Director at Rallybio Holdings LLC, Independent Director at Rallybio Corp.
(since 2018), Director at GlycoEra AG (since 2022), Secretary & Director at Precede Biosciences, Inc., Managing Partner at 5AM Venture Management LLC (since 2010), Managing Member at 5AM Partners V LLC, Advisor at Grace Science Foundation (since 2014), Managing Member at 5AM Opportunities I GP LLC, and Managing Member at 5am Partners Vi LLC.
Dr. Parmar's former job positions include Co-Chief Executive Officer & Director at 5:01 Acquisition Corp., Chairman at Homology Medicines, Inc. (2015-2022), Director at Achaogen, Inc., Director at Arvinas Operations, Inc., Director at Envoy Therapeutics, Inc., Director at Cleave Therapeutics, Inc., Independent Director at Astellas Gene Therapies, Inc. (2013-2018), Independent Director at scPharmaceuticals, Inc. (2014-2018), Director at Pulmatrix, Inc., Independent Director at Arvinas, Inc. (2013-2019), Independent Director at Vor Biopharma, Inc. (2019-2023), Independent Director at Akouos, Inc. (2017-2022), and Vice President-Strategy & Corporate Development at Novira Therapeutics LLC (2012-2015).
Dr. Parmar obtained a doctorate degree from Harvard University in 2008, a doctorate degree from Massachusetts Institute of Technology in 2010, an undergraduate degree from Princeton University in 2002, and a doctorate degree from Harvard Medical School in 2010.
Participaciones conocidas en empresas públicas
Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
---|---|---|---|---|
RALLYBIO CORPORATION
-.--% | 02/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
ENTRADA THERAPEUTICS INC
-.--% | 08/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
VOR BIOPHARMA, INC.
-.--% | 03/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Cargos activos de Kush Parmar
Empresas | Cargo | Inicio |
---|---|---|
ENTRADA THERAPEUTICS, INC. | Chairman | 01/12/2020 |
SYNGENE INTERNATIONAL LIMITED | Director/Board Member | 22/06/2021 |
RALLYBIO CORPORATION | Director/Board Member | 01/04/2018 |
AUDENTES THERAPEUTICS, INC. | Director/Board Member | 01/07/2013 |
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Private Equity Investor | 01/01/2010 |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Founder | - |
Grace Science Foundation
Grace Science Foundation Miscellaneous Commercial ServicesCommercial Services Grace Science Foundation is a biotechnology company that was founded in 2017 by Matt Wilsey and Dr. Carolyn Bertozzi. The private company is based in San Francisco, CA. The company focuses on developing novel therapies based on the function of NGLY1, a key enzyme involved in proteostasis. Grace Science Foundation's deep knowledge of the NGLY1 pathway enables them to identify new ways of treating NGLY1 deficiency as well as more common diseases. | Consultant / Advisor | 01/06/2014 |
GlycoEra AG
GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Director/Board Member | 12/07/2022 |
5am Partners Vi LLC | Corporate Officer/Principal | - |
░░░ ░░░░░░░░░░░░░ ░ ░░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
░░░ ░░░░░░░░ ░ ░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Antiguos cargos conocidos de Kush Parmar.
Empresas | Cargo | Fin |
---|---|---|
░░░ ░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░ ░░░ ░░░░ | ░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░ ░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
Formación de Kush Parmar.
Harvard University | Doctorate Degree |
Massachusetts Institute of Technology | Doctorate Degree |
Princeton University | Undergraduate Degree |
Harvard Medical School | Doctorate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 7 |
---|---|
SYNGENE INTERNATIONAL LIMITED | Commercial Services |
SCPHARMACEUTICALS INC. | Health Technology |
PULMATRIX, INC. | Health Technology |
ARVINAS, INC. | Health Technology |
VOR BIOPHARMA INC. | Health Technology |
ENTRADA THERAPEUTICS, INC. | Health Technology |
RALLYBIO CORPORATION | Health Technology |
Empresas privadas | 21 |
---|---|
Achaogen, Inc.
Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Arvinas Operations, Inc.
Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Health Technology |
5AM Venture Management LLC
5AM Venture Management LLC Investment ManagersFinance 5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US. | Finance |
Envoy Therapeutics, Inc.
Envoy Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Envoy Therapeutics, Inc. manufactures and develops therapeutic drugs for neurological and psychiatric diseases. It was founded in 2009 and is headquartered in Jupiter, FL. | Health Technology |
Cleave Therapeutics, Inc.
Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Health Technology |
Astellas Gene Therapies, Inc.
Astellas Gene Therapies, Inc. BiotechnologyHealth Technology Astellas Gene Therapies, Inc. is a biotechnology company, which engages in the development and commercialization of gene therapy products for patients with serious and rare diseases caused by single gene defects. The company was founded by Matthew R. Patterson and Thomas J. Schuetz on November 13, 2012 and is headquartered in San Francisco, CA. | Health Technology |
Cruz Blanca Initiative, Inc. | |
Homology Medicines, Inc.
Homology Medicines, Inc. Pharmaceuticals: MajorHealth Technology Homology Medicines, Inc. is a clinical-stage genetic medicines company, which engages in the translation of proprietary gene editing and gene therapy technology into novel treatments for patients with rare genetic diseases. The company was founded in March 2015 and is headquartered in Bedford, MA. | Health Technology |
5AM Partners V LLC | |
Akouos, Inc.
Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
Grace Science Foundation
Grace Science Foundation Miscellaneous Commercial ServicesCommercial Services Grace Science Foundation is a biotechnology company that was founded in 2017 by Matt Wilsey and Dr. Carolyn Bertozzi. The private company is based in San Francisco, CA. The company focuses on developing novel therapies based on the function of NGLY1, a key enzyme involved in proteostasis. Grace Science Foundation's deep knowledge of the NGLY1 pathway enables them to identify new ways of treating NGLY1 deficiency as well as more common diseases. | Commercial Services |
Rallybio LLC
Rallybio LLC Miscellaneous Commercial ServicesCommercial Services Rallybio LLC operates as a development-stage biotechnology company. The firm develops transformative therapies for patients. It focuses on bringing life-transforming medicines to patients with devastating and rare disorder. The company was founded by Martin Mackay, Stephen Uden and Jeffrey Fryer in 2018 and is headquartered in Farmington, CT. | Commercial Services |
Rallybio Holdings LLC
Rallybio Holdings LLC Medical/Nursing ServicesHealth Services Rallybio Holdings LLC engages in the provision of healthcare services. The company is headquartered in New Haven, CT. | Health Services |
5AM Opportunities I GP LLC | |
5:01 Acquisition Corp.
5:01 Acquisition Corp. Financial ConglomeratesFinance 5:01 Acquisition Corp. is a blank check emerging growth company that was formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company was founded on August 31, 2020 and is headquartered in San Francisco, CA. | Finance |
Ensoma, Inc.
Ensoma, Inc. Miscellaneous Commercial ServicesCommercial Services Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir. | Commercial Services |
Immuneel Therapeutics Pvt Ltd.
Immuneel Therapeutics Pvt Ltd. Hospital/Nursing ManagementHealth Services Immuneel Therapeutics Pvt Ltd. operates as a cancer treatment center. The company was founded by Kiran Mazumdar-Shaw, Kush M. Parmar and Siddhartha Mukherjee is headquartered in Bengaluru, India. | Health Services |
5am Partners Vi LLC | |
GlycoEra AG
GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Health Technology |
Precede Biosciences, Inc.
Precede Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Precede Biosciences is a company that aims to improve success rates in drug development and clinical practice by breaking down the barriers to precision medicine. The company is based in Boston, MA. The company seeks to redefine what can be learned from a simple blood draw to better target medicines to the right patients. Precede Biosciences is revolutionizing precision medicine by revealing unprecedented insights into disease-defining biology from a simple blood test. The CEO of the company is Rehan Verjee. | Commercial Services |
Novira Therapeutics LLC
Novira Therapeutics LLC Pharmaceuticals: MajorHealth Technology Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA. | Health Technology |
- Bolsa de valores
- Insiders
- Kush Parmar